Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paliperidone

FDA-approved product (tablet, extended release, oral), marketed as Invega, Paliperidone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Paliperidone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Mental or behavioural disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Paliperidone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paliperidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics

    NCT03730857 · start 2008-01

    Registered record
    Registry ID
    NCT03730857
    Conditions
    Schizophrenia
    Interventions
    Olanzapine; risperidone; Paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-01
    Completion
    2008-12
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionOlanzapine; risperidone; Paliperidone
    PhasePhase 1
    Registry statusCompleted

  • Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder

    NCT00592358 · start 2007-11

    Registered record
    Registry ID
    NCT00592358
    Conditions
    Pediatric Bipolar Disorder
    Interventions
    paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2007-11
    Completion
    2009-12
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Bipolar Disorder
    Interventionpaliperidone
    PhasePhase 4
    Registry statusTerminated

  • Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder

    NCT00632229 · start 2007-10

    Registered record
    Registry ID
    NCT00632229
    Conditions
    Obsessive-Compulsive Disorder
    Interventions
    Paliperidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-10
    Completion
    2013-09
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObsessive-Compulsive Disorder
    InterventionPaliperidone; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

    NCT01150448 · start 2007-09

    Registered record
    Registry ID
    NCT01150448
    Conditions
    Schizophrenia
    Interventions
    Paliperidone palmitate Treatment A; Paliperidone palmitate Treatment B
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-09
    Completion
    2009-06
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone palmitate Treatment A; Paliperidone palmitate Treatment B
    PhasePhase 1
    Registry statusCompleted

  • An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia

    NCT00473434 · start 2007-04

    Registered record
    Registry ID
    NCT00473434
    Conditions
    Schizophrenia
    Interventions
    Paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-04
    Completion
    2009-08
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

    NCT00589914 · start 2007-03

    Registered record
    Registry ID
    NCT00589914
    Conditions
    Schizophrenia
    Interventions
    RISPERDAL CONSTA; Paliperidone palmitate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    2009-06
    Enrolment
    1,221

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionRISPERDAL CONSTA; Paliperidone palmitate
    PhasePhase 3
    Registry statusCompleted

  • Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

    NCT00590577 · start 2007-03

    Registered record
    Registry ID
    NCT00590577
    Conditions
    Schizophrenia
    Interventions
    Paliperidone palmitate 25 mg eq.; Paliperidone palmitate 150 mg eq.; Placebo; Paliperidone palmitate 100 mg eq.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    2008-03
    Enrolment
    652

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone palmitate 25 mg eq.; Paliperidone palmitate 150 mg eq.; Placebo; Paliperidone palmitate 100 mg eq.
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I Disorder

    NCT00892125 · start 2006-09

    Registered record
    Registry ID
    NCT00892125
    Conditions
    Schizophrenia; Bipolar Disorder
    Interventions
    paliperidone ER; Carbamazepine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-09
    Completion
    2007-03
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Bipolar Disorder
    Interventionpaliperidone ER; Carbamazepine
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia

    NCT00396565 · start 2006-07

    Registered record
    Registry ID
    NCT00396565
    Conditions
    Schizophrenia
    Interventions
    ER OROS paliperidone; Placebo; Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-07
    Completion
    2007-11
    Enrolment
    394

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionER OROS paliperidone; Placebo; Olanzapine
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder

    NCT00309686 · start 2006-04

    Registered record
    Registry ID
    NCT00309686
    Conditions
    Affective Psychosis, Bipolar; Bipolar Disorder; Mania
    Interventions
    Paliperidone ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-04
    Completion
    2007-08
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAffective Psychosis, Bipolar; Bipolar Disorder; Mania
    InterventionPaliperidone ER
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

    NCT00309699 · start 2006-04

    Registered record
    Registry ID
    NCT00309699
    Conditions
    Bipolar Disorder; Mood Disorders
    Interventions
    Placebo; Quetiapine; Paliperidone ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-04
    Completion
    2007-11
    Enrolment
    493

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder; Mood Disorders
    InterventionPlacebo; Quetiapine; Paliperidone ER
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER

    NCT00791713 · start 2006-03

    Registered record
    Registry ID
    NCT00791713
    Conditions
    Schizophrenia
    Interventions
    Paliperidone ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-03
    Completion
    2006-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone ER
    PhasePhase 1
    Registry statusCompleted

  • A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone

    NCT00838669 · start 2005-08

    Registered record
    Registry ID
    NCT00838669
    Conditions
    Schizophrenia
    Interventions
    Extended release OROS paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-08
    Completion
    2005-12
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionExtended release OROS paliperidone
    PhasePhase 1
    Registry statusCompleted

  • A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate

    NCT01110317 · start 2005-07

    Registered record
    Registry ID
    NCT01110317
    Conditions
    Schizophrenia
    Interventions
    paliperidone palmitate 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-07
    Completion
    2006-03
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionpaliperidone palmitate 100 mg
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia

    NCT00210548 · start 2005-04

    Registered record
    Registry ID
    NCT00210548
    Conditions
    Schizophrenia
    Interventions
    paliperidone palmitate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-04
    Completion
    2006-06
    Enrolment
    366

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionpaliperidone palmitate
    PhasePhase 3
    Registry statusCompleted